The World Health Organization (WHO) today announced the start of a pilot programme to prequalify human insulin to increase treatment for diabetes in low- and middle-income countries, WHO informs.
The decision, announced ahead of World Diabetes Day (14 November), is part of a series of steps WHO will take to address the growing diabetes burden in all regions. About 65 million people with type 2 diabetes need insulin, but only half of them are able to access it, largely due to high prices. All people with type 1 diabetes need insulin to survive.
Diabetes is on the rise globally, and rising faster in low-income countries," says Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Too many people who need insulin encounter financial hardship in accessing it, or go without it and risk their lives. WHO’s prequalification initiative for insulin is a vital step towards ensuring everyone who needs this life-saving product can access it."
WHO prequalification of insulin is expected to boost access by increasing the flow of quality-assured products on the international market, providing countries with greater choice and patients with lower prices.
Insulin was discovered as a treatment for diabetes almost 100 years ago and has been on WHO’s List of Essential Medicines since it was published in 1977.
Despite an ample supply, insulin prices are currently a barrier to treatment in most low-and middle-income countries. Three manufacturers control most of the global market for insulin, setting prices that are prohibitive for many people and countries.
Data collected by WHO in 2016-2019 from 24 countries on four continents showed that human insulin was available only in 61% of health facilities and analogue insulins in 13%. The data showed that a month’s supply of insulin would cost a worker in Accra, Ghana, the equivalent of 5.5 days of pay per month, or 22% of his/her earnings.
More than 420 million people live with diabetes. Diabetes is the seventh leading cause of death and a major cause of costly and debilitating complications such as heart attacks, stroke, kidney failure, blindness and lower limb amputations.
Source: Kazinform News Agency
This information may not be reproduced without reference to Kazakhstan Today. Copyright of materials of News Agency Kazakhstan Today.
When citing our content a hyperlink to this Kazakhstan Today website is obligatory.